Member access

4-Traders Homepage  >  Shares  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Ranbaxy Laboratories Limited    RANBAXY   INE015A01028

End-of-day quote. End-of-day quote NATIONAL STOCK EXCHANGE OF INDIA - 04/23
471.15 INR   +1.41%
6h ago Novartis sales miss forecast as readies overhaul
1d ago Ranbaxy's journey as a firm to end, brands to endure
3d ago Layoffs, supply synergy key to $250 million savings in ranbaxy deal
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Ranbaxy Resumes Generic Lipitor Production for U.S.

02/22/2013 | 12:05pm US/Eastern
Recommend:
0

Ranbaxy Laboratories Ltd. (500359.BY) said Friday it has resumed manufacturing generic copies of the cholesterol-lowering drug Lipitor for the U.S. market, following a production suspension late last year after tiny glass particles were found in the product.

Ranbaxy voluntarily recalled about 480,000 bottles of generic Lipitor, also known as atorvastatin calcium, in the U.S. in November, after discovering the glass fragment problem.

An Indian unit of Japan's Daiichi Sankyo Co. (DSNKY, 4568.TO), Ranbaxy said Friday it's working with the U.S. Food and Drug Administration as it implements corrective actions designed to prevent future manufacturing problems.

Ranbaxy has commenced production of the drug substance for its atorvastatin product, as part of the first step toward resuming supplies to the U.S. market, the company said in a statement.

The recall didn't affect Ranbaxy's generic Lipitor product outside the U.S.

In January, Ranbaxy said it completed an investigation of the manufacturing problem that caused the glass particles to turn up in the product. The company previously said it suspected that a faulty tank at a facility in India caused the problem.

Ranbaxy was one of the biggest sellers of generic Lipitor in the U.S. after Pfizer Inc. (>> Pfizer Inc.) lost exclusivity for the branded product in late 2011.

But Ranbaxy's share of the generic Lipitor market has plunged to 2% from about 45% before the recall, according to J.P. Morgan, which cited data from IMS Health. Other generic companies including Mylan Inc. (>> Mylan Inc.) and Apotex Inc. have gained share of the generic Lipitor market.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Mylan Inc., Pfizer Inc.
Recommend :
0
React to this article
Latest news on RANBAXY LABORATORIES LIMIT
6h ago Novartis sales miss forecast as readies overhaul
1d ago Ranbaxy's journey as a firm to end, brands to endure
3d ago Layoffs, supply synergy key to $250 million savings in ranbaxy deal
6d ago Sun pharma makes open offer for zenotech stake
04/16 RANBAXY LABORATORIES : Eu exports to remain suspended
04/15 Ranbaxy buy triggers sun pharma's zenotech offer
04/15 `premature to talk of changes in ranbaxy management team now'
04/15 DAIICHI SANKYO : Ranbaxy-sun merger deal may close by 2014-end: daiichi
04/14DJIndia's Lupin Recalls 10,000 Bottles of Antibacterial Drugs in U.S.
04/14 RANBAXY LABORATORIES : EU BAN REMAINS ON RANBAXY's 2 PLANTS
Advertisement
Chart
Duration : Period :
Ranbaxy Laboratories Limit Technical Analysis Chart | RANBAXY | INE015A01028 | 4-Traders
Income Statement Evolution
Ranbaxy Laboratories Limit : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF